

In The Claims:

Please cancel claims 5, 11, 14-22, 39-48, 53-56, 58-62, 64 and 65 without prejudice. Applicant reserves the right to pursue this subject matter in this or any other appropriate patent application. The cancellation of these claims makes no admission regarding the patentability of this subject matter and should not be so construed.

Please add the following new claims:

66. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are MHC class I.

67. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are ICAM-1.

68. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are ICAM-2.

69. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are VCAM-1.

70. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are B7-1.

71. (New) The composition of claim 4, wherein said one or more primary and costimulatory T-cell activation molecules are B7-2.

72. (New) The composition of claim 8, wherein said bridge molecule comprises a binding site for CD28 on the surface of T cell.

73. (New) The composition of claim 8, wherein said bridge molecule comprises a binding site for 4-1BB on the surface of T cell.

74. (New) The composition of claim 9, wherein said antigens are LDL receptors.

75. (New) The composition of claim 9, wherein said antigens are gp55.

76. (New) The composition of claim 9, wherein said antigens are gp95.

77. (New) The composition of claim 9, wherein said antigens are gp115.

78. (New) The composition of claim 9, wherein said antigens are gp210.

79. (New) The composition of claim 9, wherein said antigens are CD44.

80. (New) The composition of claim 9, wherein said antigens are ICAM-1.

81. (New) The composition of claim 9, wherein said antigens are ICAM-2.

82. (New) The composition of claim 9, wherein said antigens are collagen and fibronectin receptors.

83. (New) The composition of claim 9, wherein said antigens are transferring receptors.

84. (New) The composition of claim 9, wherein said antigens are Fc receptors.

85. (New) The composition of claim 9, wherein said antigens are cytokine receptors.

86. (New) The composition of claim 13, wherein said cell is a hepatoma cell.

87. (New) The composition of claim 13, wherein said cell is a lung cancer cell.

88. (New) The composition of claim 13, wherein said cell is a gastric cancer cell.

89. (New) The composition of claim 13, wherein said cell is a colorectal cancer cell.

90. (New) The composition of claim 13, wherein said cell is a renal carcinoma cell.

91. (New) The composition of claim 13, wherein said cell is a head and neck cancer cell.

92. (New) The composition of claim 13, wherein said cell is a sarcoma cell.

93. (New) The composition of claim 13, wherein said cell is a lymphoma cell.

94. (New) The composition of claim 13, wherein said cell is a leukemia cell.

95. (New) The composition of claim 13, wherein said cell is a brain tumor cell.

96. (New) The composition of claim 13, wherein said cell is a osteosarcoma cell.

97. (New) The composition of claim 13, wherein said cell is a bladder carcinoma cell.

98. (New) The composition of claim 13, wherein said cell is a myeloma cell.

99. (New) The composition of claim 13, wherein said cell is a breast cancer cell.

100. (New) The composition of claim 13, wherein said cell is a prostate cancer cell.

101. (New) The composition of claim 13, wherein said cell is a ovarian cancer cell.

102. (New) The composition of claim 13, wherein said cell is a pancreas carcinoma cell.

## REMARKS

Applicant has cancelled without prejudice claims withdrawn from consideration by the Examiner, as well as others, in order to expedite prosecution and advance the case towards issuance. New claims have been added to more fully protect the invention. Applicant respectfully requests that these claims be given separate and independent consideration. These amendments add no new matter, are fully supported by the application as filed, and should not be construed as limiting the appropriate scope of protection under the doctrine of equivalents. As requested, Applicant has